Abstract
Dementia is considered a clinical syndrome characterized by cognitive dysfunction and memory loss. Alzheimer's disease (AD) is the most common type of dementia. AD is linked with the turbulence of diverse neurotransmitters including gamma-aminobutyric acid (GABA). Notably, GABA in the brain and cerebrospinal fluid was reduced in AD. Thus, allosteric modulation of the GABA effect by benzodiazepines (BDZs) may improve the clinical outcomes of AD patients. Therefore, the objective of the present review was to reveal the possible role of BDZs on the pathogenesis and clinical outcomes in AD patients. Though BDZs may adversely affect cognitive functions mainly in elderly patients, herein it was postulated that BDZs may have beneficial, neutral, or detrimental effects in AD. Taken together, there is strong controversy regarding the use of BDZs and the risk for the development of AD. Therefore, experimental, preclinical and clinical studies are critical to determine the potential protective or detrimental effects of BDZs on AD neuropathology.
Similar content being viewed by others
Data availability
Not applicable.
References
Aisen PS, Gauthier S, Ferris SH, Saumier D, Haine D, Garceau D, Duong A, Suhy J, Oh J, Lau WC (2011) Tramiprosate in mild-to-moderate Alzheimer’s disease–a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase study). Arch Med Sci 7:102–111
Aldaz P, Garjón J, Beitia G, Beltrán I, Librero J, Ibáñez B, Arroyo P, Ariz MJ (2021) Association between benzodiazepine use and development of dementia. Medicina Clínica (english Edition) 156:107–111
Almohaish S, Sandler M, Brophy GM (2021) Time is brain: acute control of repetitive seizures and status epilepticus using alternative routes of administration of benzodiazepines. J Clin Med 10:1754
Alsubaie N, Al-kuraishy HM, Al-Gareeb AI, Alharbi B, De Waard M, Sabatier J-M, Saad HM, Batiha GE-S (2022) Statins use in Alzheimer disease: bane or boon from frantic search and narrative review. Brain Sci 12:1290
Aranđelović J, Santrač A, Batinić B, Todorović L, Stevanović V, Tiruveedhula VVNPB, Sharmin D, Rashid F, Stanojević B, Cook JM (2022) Effects of α5 GABAA receptor modulation on social interaction, memory, and neuroinflammation in a mouse model of Alzheimer’s disease. CNS Neurosci Ther 28(11):1767–1778
Arshad S, Butt J, Iqbal J, ul Hassan SS, (2018) Abuses and misuses of benzodiazepines and antidepressents; a review. Mod Appl Pharm Pharmacol 1:1–6
Baek Y-H, Lee H, Kim WJ, Chung J-E, Pratt N, Ellett LK, Shin J-Y (2020) Uncertain association between benzodiazepine use and the risk of dementia: a cohort study. J Am Med Dir Assoc 21(201–211):e202
Barker MJ, Greenwood KM, Jackson M, Crowe SF (2004) Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis. Arch Clin Neuropsychol 19:437–454
Bellantuono C, Martellini M, Orsolini L (2019) Benzodiazepines and Z-Drugs in Pregnancy. Perinatal Psychopharmacology, Springer, Cham
Bounds CG, Nelson VL (2020) Benzodiazepines. StatPearls [Internet]. StatPearls Publishing, United States
Brady ML, Pilli J, Lorenz-Guertin JM, Das S, Moon CE, Graff N, Jacob TC (2018) Depolarizing, inhibitory GABA type a receptor activity regulates GABAergic synapse plasticity via ERK and BDNF signaling. Neuropharmacology 128:324–339
Brigo F, Lattanzi S (2020) Anticonvulsant agents: benzodiazepines (clobazam, clonazepam, diazepam, lorazepam, midazolam). NeuroPsychopharmacotherapy 2020:1–8
Caruso A, Nicoletti F, Mango D, Saidi A, Orlando R, Scaccianoce S (2018) Stress as risk factor for Alzheimer’s disease. Pharmacol Res 132:130–134
Charalambous M, Volk HA, Van Ham L, Bhatti SF (2021) First-line management of canine status epilepticus at home and in hospital-opportunities and limitations of the various administration routes of benzodiazepines. BMC Vet Res 17:1–19
Chen X-Q, Mobley WC (2019) Alzheimer disease pathogenesis: insights from molecular and cellular biology studies of oligomeric Aβ and tau species. Front Neurosci 13:659
Chen Y, Strickland MR, Soranno A, Holtzman DM (2021) Apolipoprotein E: structural insights and links to Alzheimer disease pathogenesis. Neuron 109:205–221
Cho S, Park JS, Kang Y-K (2011) Dual functions of histone-lysine N-methyltransferase Setdb1 protein at promyelocytic leukemia-nuclear body (PML-NB): maintaining PML-NB structure and regulating the expression of its associated genes. J Biol Chem 286:41115–41124
Cornett EM, Novitch MB, Brunk AJ, Davidson KS, Menard BL, Urman RD, Kaye AD (2018) New benzodiazepines for sedation. Best Pract Res Clin Anaesthesiol 32:149–164
Dailly E, Bourin M (2008) The use of benzodiazepines in the aged patient: clinical and pharmacological considerations. Pak J Pharm Sci 21:144–150
De Gage SB, Moride Y, Ducruet T, Kurth T, Verdoux H, Tournier M, Pariente A, Bégaud B (2014) Benzodiazepine use and risk of Alzheimer’s disease: case-control study. BMJ 349:g5205
Defrancesco M, Marksteiner J, Fleischhacker WW, Blasko I (2015) Use of benzodiazepines in Alzheimer’s disease: a systematic review of literature. Int J Neuropsychopharmacol 18:pyv055
Delgado-Roche L, Santes-Palacios R, Herrera JA, Hernández SL, Riera M, Fernández MD, Mesta F, Garrido G, Rodeiro I, Espinosa-Aguirre JJ (2020) Interaction of Thalassia testudinum metabolites with cytochrome P450 enzymes and its effects on benzo (a) pyrene-induced mutagenicity. Mar Drugs 18:566
Della Torre C, Maggioni D, Ghilardi A, Parolini M, Santo N, Landi C, Madaschi L, Magni S, Tasselli S, Ascagni M (2018) The interactions of fullerene C60 and Benzo (α) pyrene influence their bioavailability and toxicity to zebrafish embryos. Environ Pollut 241:999–1008
Desmidt T, Delrieu J, Lebouvier T, Robert G, David R, Balageas A-C, Surget A, Belzung C, Arlicot N, Ribeiro M-J (2019) Benzodiazepine use and brain amyloid load in nondemented older individuals: a florbetapir PET study in the multidomain Alzheimer preventive trial cohort. Neurobiol Aging 84:61–69
Diehl T, Mullins R, Kapogiannis D (2017) Insulin resistance in Alzheimer’s disease. Transl Res 183:26–40
Duka T, Ott H, Rohloff A, Voet B (1996) The effects of a benzodiazepine receptor antagonist β-carboline ZK-93426 on scopolamine-induced impairment on attention, memory and psychomotor skills. Psychopharmacology 123:361–373
Dyer AH, Murphy C, Lawlor B, Kennelly SP, Segurado R, Kennelly S, Rikkert MGO, Howard R, Pasquier F, Börjesson-Hanson A (2020) Cognitive outcomes of long-term benzodiazepine and related drug (BDZR) use in people living with mild to moderate Alzheimer’s disease: results from NILVAD. J Am Med Dir Assoc 21:194–200
Edinoff AN, Nix CA, Hollier J, Sagrera CE, Delacroix BM, Abubakar T, Cornett EM, Kaye AM, Kaye AD (2021) Benzodiazepines: uses, dangers, and clinical considerations. Neurol Int 13:594–607
Edinoff AN, Nix CA, Odisho AS, Babin CP, Derouen AG, Lutfallah SC, Cornett EM, Murnane KS, Kaye AM, Kaye AD (2022) Novel designer benzodiazepines: comprehensive review of evolving clinical and adverse effects. Neurol Int 14:648–663
Etherington L-A, Mihalik B, Pálvölgyi A, Ling I, Pallagi K, Kertész S, Varga P, Gunn BG, Brown AR, Livesey MR (2017) Selective inhibition of extra-synaptic α5-GABAA receptors by S44819, a new therapeutic agent. Neuropharmacology 125:353–364
Ettcheto M, Olloquequi J, Sánchez-López E, Busquets O, Cano A, Manzine PR, Beas-Zarate C, Castro-Torres RD, García ML, Bulló M (2020) Benzodiazepines and related drugs as a risk factor in Alzheimer’s disease dementia. Front Aging Neurosci 11:344
Fastbom J, Forsell Y, Winblad B (1998) Benzodiazepines may have protective effects against Alzheimer disease. Alzheimer Dis Assoc Disord 12:14–17
Frias AT, Fernandes GG, Zangrossi H Jr (2019) GABAA/benzodiazepine receptors in the dorsal periaqueductal gray mediate the panicolytic but not the anxiolytic effect of alprazolam in rats. Behav Brain Res 364:99–105
Frost D, Meechoovet B, Wang T, Gately S, Giorgetti M, Shcherbakova I, Dunckley T (2011) β-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer’s disease-related sites. PLoS ONE 6:e19264
Gallacher J, Elwood P, Pickering J, Bayer A, Fish M, Ben-Shlomo Y (2012) Benzodiazepine use and risk of dementia: evidence from the Caerphilly Prospective Study (CaPS). J Epidemiol Comm Health 66:869–873
Gallet Q, Bouteloup V, Locatelli M, Habert M-O, Chupin M, Delrieu J, Lebouvier T, Robert G, David R, Bulteau S (2022) Benzodiazepine use and neuroimaging markers of Alzheimer’s disease in nondemented older individuals: an MRI and 18F Florbetapir PET study in the MEMENTO cohort. Neuropsychopharmacology 47:1114–1120
Gomiero A, Strafella P, Pellini G, Salvalaggio V, Fabi G (2018) Comparative effects of ingested PVC micro particles with and without adsorbed benzo (a) pyrene vs spiked sediments on the cellular and sub cellular processes of the benthic organism Hediste diversicolor. Frontiers in Mar Sci 5:99
Gonzalez J, Upadhyaya VD, Manna ZT, Sharma AR, Christopher J, Douedi S, Sen S (2022) Paradoxical excitation following intravenous lorazepam administration for alcohol withdrawal–a case presentation and literature review. J Pharm Pract. https://doi.org/10.1177/08971900221097182
Guerrini G, Ciciani G, Cambi G, Bruni F, Selleri S, Guarino C, Melani F, Montali M, Martini C, Ghelardini C (2009) Synthesis, in vivo evaluation, and molecular modeling studies of new pyrazolo [5, 1-c][1, 2, 4] benzotriazine 5-oxide derivatives. Identification of a bifunctional hydrogen bond area related to the inverse agonism. J Med Chem 52:4668–4682
Harris D, Clayton T, Cook J, Sahbaie P, Halliwell RF, Furtmüller R, Huck S, Sieghart W, DeLorey TM (2008) Selective influence on contextual memory: physiochemical properties associated with selectivity of benzodiazepine ligands at GABAA receptors containing the α5 subunit. J Med Chem 51:3788–3803
Henstridge CM, Hyman BT, Spires-Jones TL (2019) Beyond the neuron–cellular interactions early in Alzheimer disease pathogenesis. Nat Rev Neurosci 20:94–108
Islam MM, Iqbal U, Walther B, Atique S, Dubey NK, Nguyen P-A, Poly TN, Masud JHB, Li Y-CJ, Shabbir S-A (2016) Benzodiazepine use and risk of dementia in the elderly population: a systematic review and meta-analysis. Neuroepidemiology 47:181–191
Izza MA, Lunt E, Gordon AL, Gladman JR, Armstrong S, Logan P (2020) Polypharmacy, benzodiazepines, and antidepressants, but not antipsychotics, are associated with increased falls risk in UK care home residents: a prospective multi-centre study. Eur Geriatr Med 11:1043–1050
Ji B, Liu S, Xue Y, He X, Man VH, Xie X-Q, Wang J (2019) Prediction of drug–drug interactions between opioids and overdosed benzodiazepines using physiologically based pharmacokinetic (PBPK) modeling and simulation. Drugs R&d 19:297–305
Joyce G, Ferido P, Thunell J, Tysinger B, Zissimopoulos J (2022) Benzodiazepine use and the risk of dementia. Alzheimer’s Dementia 8:e12309
Keskin E, Can EY, Aydın HA, Işık E, Özgen U, Şimşek K, Cengil O, Başar C, Kalaycı M (2021) The preventative effect of of Ro5-4864 (peripheral benzodiazepine receptor agonist) on spinal epidural fibrosis after laminectomy in a rat model. Neurol Res 43:1107–1115
Kleinberger G, Wils H, Ponsaerts P, Joris G, Timmermans JP, Van Broeckhoven C, Kumar-Singh S (2010) Increased caspase activation and decreased TDP-43 solubility in progranulin knockout cortical cultures. J Neurochem 115:735–747
Knopman DS, Amieva H, Petersen RC, Chételat G, Holtzman DM, Hyman BT, Nixon RA, Jones DT (2021) Tendinopathy. Nat Rev Dis Primers 7:1–21
Kramer PF, Twedell EL, Shin JH, Zhang R, Khaliq ZM (2020) Axonal mechanisms mediating γ-aminobutyric acid receptor type a (GABA-A) inhibition of striatal dopamine release. Elife. https://doi.org/10.7554/eLife.55729
Kurlawala Z, Roberts JA, McMillan JD, Friedland RP (2018) Diazepam toxicity presenting as a dementia disorder. J Alzheimers Dis 66:935–938
Kwakowsky A, Calvo-Flores Guzmán B, Pandya M, Turner C, Waldvogel HJ, Faull RL (2018a) GABAA receptor subunit expression changes in the human Alzheimer’s disease hippocampus, subiculum, entorhinal cortex and superior temporal gyrus. J Neurochem 145:374–392
Kwakowsky A, Guzmán BC-F, Govindpani K, Waldvogel HJ, Faull RL (2018b) Gamma-aminobutyric acid a receptors in Alzheimer’s disease: highly localized remodeling of a complex and diverse signaling pathway. Neural Regen Res 13:1362
Kwakowsky A, Waldvogel HJ, Faull RL (2021) Therapeutic potential of alpha 5 subunit containing GABAA receptors in Alzheimer’s disease. Neural Regen Res 16:1550
Lamvu G, Soliman AM, Manthena SR, Gordon K, Knight J, Taylor HS (2019) Patterns of prescription opioid use in women with endometriosis: evaluating prolonged use, daily dose, and concomitant use with benzodiazepines. Obstet Gynecol 133:1120
Lee BY, Ban JY, Seong YH (2005) Chronic stimulation of GABAA receptor with muscimol reduces amyloid β protein (25–35)-induced neurotoxicity in cultured rat cortical cells. Neurosci Res 52:347–356
LeQuang JA (2021) The effects of benzodiazepines on memory. Naturally occurring benzodiazepines, endozepines, and their receptors. CRC Press, Boca Raton
Li G, Bien-Ly N, Andrews-Zwilling Y, Xu Q, Bernardo A, Ring K, Halabisky B, Deng C, Mahley RW, Huang Y (2009) GABAergic interneuron dysfunction impairs hippocampal neurogenesis in adult apolipoprotein E4 knockin mice. Cell Stem Cell 5:634–645
Li Y, Ma J, Jin Y, Li N, Zheng R, Mu W, Wang J, Si JH, Chen J, Shang HC (2020) Benzodiazepines for treatment of patients with delirium excluding those who are cared for in an intensive care unit. The Cochrane Database Sys Rev 2:Cd012670
Lin YH, Chen MH, Chang YC, Chen L, Hsiung CA, Wu SI (2022) Prevalence of exposure to benzodiazepines among pregnant women in Taiwan: a nationwide longitudinal study. J Sleep Res. https://doi.org/10.1111/jsr.13678
Lombardi N, Bettiol A, Crescioli G, Ravaldi C, Bonaiuti R, Venegoni M, Vighi GD, Mugelli A, Mannaioni G, Vannacci A (2020) Risk of hospitalisation associated with benzodiazepines and z-drugs in Italy: a nationwide multicentre study in emergency departments. Intern Emerg Med 15:1291–1302
Manchester KR, Maskell PD, Waters L (2018) Experimental versus theoretical log D7. 4, pKa and plasma protein binding values for benzodiazepines appearing as new psychoactive substances. Drug Test Anal 10:1258–1269
Marsh J, Alifragis P (2018) Synaptic dysfunction in Alzheimer’s disease: the effects of amyloid beta on synaptic vesicle dynamics as a novel target for therapeutic intervention. Neural Regen Res 13:616
Mohamad FH, Has ATC (2019) The α5-containing GABAA receptors—a brief summary. J Mol Neurosci 67:343–351
Moustafa RE, Tarbah F, Saeed HS, Sharif SI (2021) Designer benzodiazepines versus prescription benzodiazepines: can structural relation predict the next step? Crit Rev Toxicol 51:249–263
Nafti M, Sirois C, Kröger E, Carmichael P-H, Laurin D (2020) Is benzodiazepine use associated with the risk of dementia and cognitive impairment–not dementia in older persons? The Canadian study of health and aging. Ann Pharmacother 54:219–225
Noguchi Y, Ueno A, Katsuno H, Otsubo M, Yoshida A, Kanematsu Y, Sugita I, Tachi T, Tsuchiya T, Teramachi H (2018) Analyses of non-benzodiazepine-induced adverse events and prognosis in elderly patients based on the Japanese adverse drug event report database. J Pharmaceut Health Care Sci 4:10
Ochoa-de la Paz LD, Gulias-Cañizo R, Ruíz-Leyja ED, Sánchez-Castillo H, Parodí J (2021) The role of GABA neurotransmitter in the human central nervous system, physiology, and pathophysiology. Revista Mexicana De Neurociencia 22:67–76
Pomara N, Bruno D, Sidtis JJ, Lutz MW, Greenblatt DJ, Saunders AM, Roses AD (2011) Translocase of outer mitochondrial membrane 40 homolog (TOMM40) poly-T length modulates lorazepam-related cognitive toxicity in healthy APOE ε4-negative elderly. J Clin Psychopharmacol 31:544–546
Qu J, Yan H, Zheng Y, Xue F, Zheng Y, Fang H, Chang Y, Yang H, Zhang J (2018) The molecular mechanism of alpha-synuclein dependent regulation of protein phosphatase 2A activity. Cell Physiol Biochem 47:2613–2625
Ratner MH, Downing SS, Guo O, Odamah KE, Stewart TM, Kumaresan V, Robitsek RJ, Xia W, Farb DH (2021) Prodromal dysfunction of α5GABA-A receptor modulated hippocampal ripples occurs prior to neurodegeneration in the TgF344-AD rat model of Alzheimer’s disease. Heliyon 7:e07895
Richardson K, Loke Y, Savva GM, Howard RJ, Boyd P, Aldus C, Maidment ID, Steel N, Arthur A, Ballard C (2018) P4–387: UNINTENDED EFFECTS OF Z-DRUGS (ZOLPIDEM, ZOPICLONE AND ZALEPLON) IN PEOPLE LIVING WITH DEMENTIA. Alzheimers Dement 14:P1622–P1622
Rissman RA, De Blas AL, Armstrong DM (2007) GABAA receptors in aging and Alzheimer’s disease. J Neurochem 103:1285–1292
Saarelainen L, Tolppanen AM, Koponen M, Tanskanen A, Tiihonen J, Hartikainen S, Taipale H (2018) Risk of death associated with new benzodiazepine use among persons with Alzheimer disease: a matched cohort study. Int J Geriatr Psychiatry 33:583–590
Salzman CE, Lebowitz BD (1991) Anxiety in the elderly: Treatment and research. The chapters were prepared and presented at a small workshop in Boston in Jan 1989. Springer Publishing Company, Cham
Salzman C (2020) Do benzodiazepines cause Alzheimer’s disease? : Am psychiatric assoc. Am J Psyc. https://doi.org/10.1176/appi.ajp.2020.20040375
Savić MM, Majumder S, Huang S, Edwankar RV, Furtmüller R, Joksimović S, Clayton T Sr, Ramerstorfer J, Milinković MM, Roth BL (2010) Novel positive allosteric modulators of GABAA receptors: Do subtle differences in activity at α1 plus α5 versus α2 plus α3 subunits account for dissimilarities in behavioral effects in rats? Prog Neuropsychopharmacol Biol Psychiatry 34:376–386
Schieveld JN, Strik JJ, Bruining H (2018) On benzodiazepines, paradoxical agitation, hyperactive delirium, and chloride homeostasis. Crit Care Med 46:1558–1559
Sieghart W, Savić MM (2018) International Union of Basic and Clinical Pharmacology. CVI: GABA(A) Receptor Subtype- and Function-selective Ligands: Key Issues in Translation to Humans. Pharmacol Rev 70:836–878
Smith AJ, Tett SE (2009) How do different age groups use benzodiazepines and antidepressants? Analysis of an Australian administrative database, 2003–6. Drugs Aging 26:113–122
Sontag J-M, Sontag E (2014) Protein phosphatase 2A dysfunction in Alzheimer’s disease. Front Mol Neurosci 7:16
Stonnington CM, Snyder PJ, Hentz JG, Reiman EM, Caselli RJ (2009) Double-blind crossover study of the cognitive effects of lorazepam in healthy apolipoprotein E (APOE)-ε4 carriers. J Clin Psychiatry 70:4746
Tanimukai H, Grundke-Iqbal I, Iqbal K (2005) Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer’s disease. Am J Pathol 166:1761–1771
Tiwari S, Atluri V, Kaushik A, Yndart A, Nair M (2019) Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics. Int J Nanomed 14:5541
Trevisan K, Cristina-Pereira R, Silva-Amaral D, Aversi-Ferreira TA (2019) Theories of aging and the prevalence of Alzheimer’s disease. BioMed Res Int 2019:1–9
Vatanabe I, Manzine P, Cominetti M (2020) Historic concepts of dementia and Alzheimer’s disease: from ancient times to the present. Rev Neurol (paris) 176:140–147
Vellas B, Sol O, Snyder JP, Ousset P-J, Haddad R, Maurin M, Lemarié J-C, Désiré L, Pando PM (2011) EHT0202 in Alzheimer’s disease: a 3 month, randomized, placebo-controlled, double-blind study. Curr Alzheimer Res 8:203–212
Vlad CS, Dumitrascu V, Vlad DC, Cimporescu A, Popescu R, Dehelean L, Marincu I, Citu IM, POENARU D, (2017) Fast and simple method for simultaneous detection and quantification of diazepam and desmethyldiazepam in plasma samples in psychiatric patients by GC-MS-FID. Rev Chim (bucharest) 68:530–533
Vöglein J, Ricard I, Noachtar S, Kukull WA, Dieterich M, Levin J, Danek A (2020) Seizures in Alzheimer’s disease are highly recurrent and associated with a poor disease course. J Neurol 267:2941–2948
Wan H, Warburton E, Zhu X, Koder T, Park Y, Aggleton JP, Cho K, Bashir Z, Brown M (2004) Benzodiazepine impairment of perirhinal cortical plasticity and recognition memory. Eur J Neurosci 20:2214–2224
Whittington RA, Virág L, Gratuze M, Lewkowitz-Shpuntoff H, Cheheltanan M, Petry F, Poitras I, Morin F, Planel E (2019) Administration of the benzodiazepine midazolam increases tau phosphorylation in the mouse brain. Neurobiol Aging 75:11–24
Wick J (2013) The history of benzodiazepines. The Consul Pharm 28:538–548
Williams AM (2018) Coadministration of intramuscular olanzapine and benzodiazepines in agitated patients with mental illness. Mental Health Clin 8:208–213
Williams T, Borchelt DR, Chakrabarty P (2020) Therapeutic approaches targeting apolipoprotein E function in Alzheimer’s disease. Mol Neurodegener 15:1–19
Wingo AP, Liu Y, Gerasimov ES, Gockley J, Logsdon BA, Duong DM, Dammer EB, Robins C, Beach TG, Reiman EM (2021) Integrating human brain proteomes with genome-wide association data implicates new proteins in Alzheimer’s disease pathogenesis. Nat Genet 53:143–146
Xu Y, Lavrencic L, Radford K, Booth A, Yoshimura S, Anstey KJ, Anderson CS, Peters R (2021) Systematic review of coexistent epileptic seizures and Alzheimer’s disease: Incidence and prevalence. J Am Geriatr Soc 69:2011–2020
Yamazaki Y, Zhao N, Caulfield TR, Liu C-C, Bu G (2019) Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol 15:501–518
Yoshiike Y, Kimura T, Yamashita S, Furudate H, Mizoroki T, Murayama M, Takashima A (2008) GABAA receptor-mediated acceleration of aging-associated memory decline in APP/PS1 mice and its pharmacological treatment by picrotoxin. PLoS ONE 3:e3029
Zhang Y, Shao H, Dong Y, Swain CA, Yu B, Xia W, Xie Z (2014) Chronic treatment with anesthetic propofol attenuates β-amyloid protein levels in brain tissues of aged mice. Transl Neurodegener 3:1–7
Zhao Y, Wang Z, Dai J, Chen L, Huang Y, Zhan Z (2012) Beneficial effects of benzodiazepine diazepam on chronic stress-induced impairment of hippocampal structural plasticity and depression-like behavior in mice. Behav Brain Res 228:339–350
Acknowledgements
None.
Funding
None.
Author information
Authors and Affiliations
Contributions
HMA-K and AIA conceptualized the manuscript, wrote, edited and reviewed the main text and approved the final edition of the manuscript. HMS and GE-SB prepared the figures, wrote, corrected, amended and approved the final edition of the manuscript.
Corresponding authors
Ethics declarations
Conflicts of interest
The authors declare no conflict of interest.
Informed consent statement
Not applicable.
Institutional review board statement
None.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Al-kuraishy, H.M., Al-Gareeb, A.I., Saad, H.M. et al. Benzodiazepines in Alzheimer’s disease: beneficial or detrimental effects. Inflammopharmacol 31, 221–230 (2023). https://doi.org/10.1007/s10787-022-01099-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10787-022-01099-4